MONOVISC® is generally well tolerated, with a low incidence of adverse events. The product has a strong safety profile due to its high purity and non-animal origin. It is both CE-marked and FDA-approved for intra-articular use. When administered by trained professionals under sterile conditions, MONOVISC® carries minimal risk. Side effects are rare and usually mild, typically resolving within a few days.

Home - MONOVISC®

MONOVISC®

Q: What is MONOVISC®, and How Does It Work?

MONOVISC® is a single-injection hyaluronic acid-based viscosupplement designed for the treatment of pain associated with osteoarthritis of the knee. It is composed of ultra-pure, high molecular weight sodium hyaluronate derived from a non-animal source, making it highly biocompatible and well tolerated. When injected into the affected joint, MONOVISC® replenishes synovial fluid, which becomes degraded in osteoarthritic conditions. The hyaluronic acid in MONOVISC® acts as a lubricant and shock absorber, reducing friction and allowing smoother, pain-free movement. Additionally, it provides a cushioning effect that helps protect joint tissues and reduces inflammation over time.

Q: What Is MONOVISC® Used For?

MONOVISC® is specifically indicated for: Treating knee pain in patients with osteoarthritis who have not responded adequately to conservative therapy (e.g., physical therapy or analgesics) Providing sustained joint lubrication and cushioning Enhancing mobility and comfort in daily activities It is a preferred option for patients seeking relief without surgical intervention or those needing an alternative to systemic pain medications.

Q: Why Choose This Brand?

MONOVISC® stands out in the viscosupplement market for its ease of use, single-injection protocol, and long-lasting effectiveness. It is produced using a patented cross-linking technology that enhances its viscoelastic properties while maintaining safety and tolerability. Key benefits of MONOVISC® include: Single-dose convenience, reducing patient visits Non-animal derived HA, minimizing allergy risk High molecular weight formulation for optimal performance Clinically proven results lasting up to six months FDA-approved and CE-marked MONOVISC® offers a streamlined and effective option for managing osteoarthritis-related joint pain.

Q: How Long Do Results Last?

Most patients experience relief within days following the injection, with peak improvement occurring after 2 to 4 weeks. Clinical studies show that a single MONOVISC® injection can provide pain relief for up to six months , depending on the severity of osteoarthritis and the patient’s physical activity levels. Ongoing evaluations may determine the need for reapplication after the therapeutic window ends.

Best sellers

All brands

Brand: MONOVISC® products

MONOVISC®
€314.00 Add to cart

MONOVISC®

MONOVISC Injection Administering Techniques

MONOVISC® is administered via a single intra-articular injection directly into the knee joint space. Proper technique is essential for optimal results and includes:

Identifying the anatomical landmarks of the joint
Aspiration of any excess synovial fluid before injection
Using a sterile, 18–21 gauge needle to inject the MONOVISC product
Post-injection patient monitoring to confirm tolerability

This procedure should only be performed by qualified healthcare professionals trained in joint injection protocols.

MONOVISC Product Range

MONOVISC® 4 mL Syringe: A single-use, prefilled syringe containing 88 mg of ultra-pure sodium hyaluronate acid in a 4 mL solution. Designed for one-time intra-articular injection for the knee.

Currently, MONOVISC® is offered as a single-MONOVISC product formulation specifically tailored for osteoarthritis of the knee.

MONOVISC Injection Side Effects

Most side effects are mild and short-term, including:

Temporary joint stiffness or swelling
Mild pain or discomfort at the MONOVISC injection site
Redness or bruising around the knee area

Serious reactions are extremely rare when sterile technique and proper patient screening are applied.

MONOVISC® vs Competition

MONOVISC® differs from other viscosupplements in several ways:

It requires only one injection, whereas many competitors require three to five.
The non-animal-sourced HA formulation reduces immunogenicity risks.
Its patented cross-linking technology offers extended residence time and improved pain efficacy.
It is backed by robust clinical data and global regulatory approvals, making it easy to buy MONOVISC with confidence.

Compared to other HA-based injectables used in osteoarthritis, MONOVISC® offers the advantage of convenience, compliance, and long-lasting relief—all essential attributes in modern pain management practices.